The Optimal Route of Administration of the Glycoprotein IIb/IIIa Receptor Antagonist Abciximab During Percutaneous Coronary Intervention; Intravenous Versus Intracoronary

Keyphrases

• Route of Administration 100%
• Percutaneous Coronary Intervention 100%
• Glycoprotein IIb/IIIa Inhibitors 100%
• Abciximab 100%
• Intracoronary 100%
• Inflammatory Pathways 16%
• Randomized Trial 16%
• Acute Coronary Syndrome 16%
• Beneficial Effects 16%
• Clinical Trials 16%
• Anticoagulants 16%
• Thrombus Formation 16%
• Potent Inhibitor 16%
• Intracoronary Administration 16%
• Intravenous Bolus 16%
• Pharmacological Mechanism 16%
• Platelet Aggregation 16%
• First Dose 16%
• Platelet Thrombus 16%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor Antagonist 100%
• Route of Administration 100%
• Abciximab 100%
• Fibrinogen Receptor 100%
• Retrospective Study 16%
• Acute Coronary Syndrome 16%
• Anticoagulant Agent 16%
• Clinical Trial 16%
• Thrombus 16%